A

Akari Therapeutics plc
D

AKTX

1.16000
USD
-0.02
(-1.69%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
37,324,589
أصول ذات صلة
A
ACIU
0.07000
(3.50%)
2.07000 USD
A
AXGN
-0.180
(-1.63%)
10.895 USD
B
BHC
-0.14000
(-1.97%)
6.98000 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
C
CETX
0.01000
(0.82%)
1.23000 USD
C
COCP
-0.01000
(-0.67%)
1.49000 USD
C
CPRX
0.020
(0.09%)
21.460 USD
C
CTRM
0.03000
(1.35%)
2.25000 USD
C
CTXR
0.09000
(4.27%)
2.20000 USD
D
DARE
0.02000
(0.84%)
2.40000 USD
E
EVOK
-0.16000
(-6.02%)
2.50000 USD
I
ICAD
0.03500
(0.94%)
3.77000 USD
I
INMD
0.005
(0.03%)
15.210 USD
K
KTOS
1.380
(3.19%)
44.660 USD
L
LXRX
0.00020
(0.02%)
0.91110 USD
O
OPRX
0.326
(2.49%)
13.430 USD
O
OVID
0.00830
(2.51%)
0.33880 USD
P
PAAS
0.230
(0.80%)
29.020 USD
P
PLAG
-0.06000
(-6.98%)
0.80000 USD
R
REKR
0.03000
(2.50%)
1.23000 USD
R
RGEN
0.490
(0.39%)
127.440 USD
S
SCYX
0.02160
(2.99%)
0.74490 USD
S
SHIP
0.01000
(0.15%)
6.48000 USD
S
SINT
0.06000
(1.80%)
3.39000 USD
S
SSKN
-0.08000
(-3.27%)
2.37000 USD
T
TLRY
0.03700
(7.54%)
0.52800 USD
T
TNXP
0.140
(0.40%)
35.290 USD
T
TTNP
0.07000
(1.65%)
4.32000 USD
U
USIO
0.01000
(0.61%)
1.64000 USD
المزيد
الأخبار المقالات

العنوان: Akari Therapeutics plc

القطاع: Healthcare
الصناعة: Biotechnology
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.